The application of high-pressure liquid chromatography assays for cephalosporin serum concentrations is difficult in uremic patients because of interference from nondialyzable substances. We developed a highpressure liquid chromatography method for determining the serum concentration of ceftizoxime in normal and uremic patients. The method involves protein precipitation with acetonitrile, followed by removal of the acetonitrile with dichloromethane. Separation was accomplished with a reverse-phase (C-18) column and a mobile phase of 13% acetonitrile and 2.8% acetic acid. UV detection at 310 nm was used to monitor the peaks. This assay produced a linear relationship between peak height ratio and ceftizoxime concentration from 1.5 to 100 ,ug/ml. Samples from 30 patients were assayed by this method and by a bioassay, with a good correlation of results (r = 0.9832). The method was applicable equally to normal and uremic serum samples.
The application of high-pressure liquid chromatography assays for cephalosporin serum concentrations is difficult in uremic patients because of interference from nondialyzable substances. We developed a highpressure liquid chromatography method for determining the serum concentration of ceftizoxime in normal and uremic patients. The method involves protein precipitation with acetonitrile, followed by removal of the acetonitrile with dichloromethane. Separation was accomplished with a reverse-phase (C-18) column and a mobile phase of 13% acetonitrile and 2.8% acetic acid. UV detection at 310 nm was used to monitor the peaks. This assay produced a linear relationship between peak height ratio and ceftizoxime concentration from 1.5 to 100 ,ug/ml. Samples from 30 patients were assayed by this method and by a bioassay, with a good correlation of results (r = 0.9832). The method was applicable equally to normal and uremic serum samples.
Ceftizoxime (FK-749) is a new broad-spectrum semisynthetic cephalosporin antibiotic with beta-lactamase stability. Ceftizoxime is not metabolized and is cleared from the body primarily by the kidneys by both filtration and secretion. For this reason, measurement of serum levels may be desirable in the management of patients with decreased renal function.
Various biological assays have been reported for the quantitation of ceftizoxime in serum; however, this type of assay is generally time-consuming and subject to interference from other antibiotics. High-pressure liquid chromatography (HPLC) assays for the measurement of antibiotics have definite advantages over bioassays in precision, specificity, and rapidity.
Numerous HPLC assays (8) have been developed for the currently available cephalosporins; most of these use UV detection and either reverse-phase or ion-pair chromatography. The major differences art in sample preparation procedures. Protein precipitation with acids or organic solvents (7), anion-exchange columns (3), and extraction with various solvents (2) have all been used in sample clean-up. In addition to well-described difficulties with incomplete recovery and sample dilution, others have shown that serum samples from patients with end-stage renal disease (ESRD) have significant interferences when UV detection methods (5) are used.
The purpose of the present report is to describe an HPLC method for the quantitation of ceftizoxime which is simple, rapid, and, due to the wavelength used for detection, free from interference in samples from ESRD patients.
MATERIALS AND METHODS
Reagents. Acetonitrile, dichloromethane (both HPLC grade), and glacial acetic acid were obtained from Fisher Scientific Co., Pittsburgh Peak heights were measured manually, and linear regression analysis of the peak height ratio of ceftizoxime to ihternal standard was used to form a standard curve from which an unknown sample concentration could be determined. 
RESULTS
Chromatography. Figure 1 shows typical chromatograms of predose and postdose sera of patients with normal kidney function. The retention times were 6.0 min for the ceftizoxime and 9 min for the internal standard. Fifteen sera from patients not receiving ceftizoxime were analyzed for possible interferences, and none was found. Figure 2 shows typical chromatograms of patients with ESRD. Fifteen sera from ESRD patients were tested, and all had interferences at 254 nm which could be eliminated by changing the wavelength to 310 nm.
Linearity. There was a linear relationship between peak height ratios and ceftizoxime concentration from 1.5 to 100 ,ug/ml. Samples with higher amounts of ceftizoxime could be diluted before assay. Linear regression analysis of a typical standard curve resulted in a line with the equation y = 0.018x + 0.0162; r = 0.993.
Precision. The precision of the method was determined by assays of pooled human sera spiked with ceftizoxime on the same day and over a period of several weeks (Table 1) .
Specificity. Table 2 lists several cephalosporins that could also be detected by this assay. Other compounds which could not be detected at a concentration of 100 ,ug/ml were aminoglycosides (gentamicin, tobramycin, and amikacin), clindamycin, erythromycin, vancomycin, penicillin, cefo-Iz perazone, piperacillin, ticarcillin, carbenicillin, and apalcillin.
Method comparison. Results obtained by the HPLC method were compared with those previously obtained by bioassay for 30 serum samples (4) which had been stored at -70°C for up to 2 years. No change in bioactivity was detected. Bivariate regression analysis of the paired results revealed good correlation between the two methods (r = 0.9832) and insignificant bias (0.46 ,ug/ml).
Recovery studies. Relative and analytical recovery rates of ceftizoxime were evaluated by adding 50 pg of ceftizoxime per ml to distilled water and to serum and assaying each six times. The spiked water was assayed before and after extraction. Analytical recovery, as calculated by peak height ratio in a serum versus water matrix, was 98 ± 2%. The relative recovery of ceftizoxime was 106 ± 3% and the relative recovery of the internal standard was 107 ± 3.5%. 
DISCUSSION
We found that the development of an HPLC assay for ceftizoxime in the sera of ESRD patients was complicated by interfering peaks. Two previous reports of HPLC assays for ceftizoxime (3, 6) do not discuss any interference found in sera of ESRD patients; however, neither stated whether any such specimens were assayed. A similar problem was observed in measuring moxalactam in the sera of ESRD patients by HPLC (5). The interfering peaks were observed in the sera of all ESRD patients and did not seem to be related to medications, but rather to the inefficiency of dialysis. In our assay, optimization of mobile-phase pH and detector wavelength was used to eliminate these interferences. Decreasing the pH of the mobile phase to 2.8 (below the pKa [1] of ceftizoxime) resulted in an increase in the retention time of the ceftizoxime without,affecting the interfering peaks, and changing the wavelength from 254 to 310 nm eliminated any interferences from endogenous compounds (1) . Although the absorbance of ceftizoxime at 310 nm is only about one-third of that at 254 nm, the loss in sensitivity was easily compensated for by the increased peak efficiency obtained with the low pH mobile phase. Use of a mobile phase with a higher pH resulted in considerable peak tailing. The low pH had not affected column efficiency after 400 samples were analyzed.
Deproteinization of serum with acetonitrile has been used by other workers to avoid any pH extremes of acid precipitation which might effect the stability of ceftizoxime. The protein-free extract containing acetonitrile must be modified to reduce the percentage of acetonitrile. We chose to remove the acetonitrile with dichloromethane because dichloromethane extraction did not dilute the sample. The resulting aqueous layer contained ceftizoxime in approximately the same concentration as that of the original serum specimen, and therefore allowed a more sensitive determination of ceftizoxime. Analytical evaluation of the assay demonstrates the precision, linearity, accuracy, and recovery of the method. The only antibiotics tested that interfered with the assay were cefazolin and cephapirin, which would not normally be administered concomitantly with ceftizoxime. The proposed method is applicable to therapeutic monitoring of ceftizoxime as well as to pharmacokinetic studies.
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